The Economic Costs of Overactive Bladder in Germany

• Published in: European urology Vol. 51; no. 6; pp. 1654 - 1663
• Main Authors: Klotz, Theodor, Brüggenjürgen, Bernd, Burkart, Martin, Resch, Ansgar
• Format: Journal Article
• Language: English
• Published: Switzerland Elsevier B.V 01-06-2007
• Subjects: Bladder dysfunction; Comorbidity; Cost of Illness; Costs and Cost Analysis; Female; Germany - epidemiology; Health Care Costs; Healthcare costs; Humans; Incontinence; Male; Models, Economic; Overactive bladder; Prevalence; Urinary Bladder, Overactive - economics; Urinary Bladder, Overactive - epidemiology; Urinary Bladder, Overactive - therapy; Urology; Germany; Overactive bladder; Incontinence; Healthcare costs; Bladder dysfunction
• ISSN: 0302-2838; 1873-7560
• DOI: 10.1016/j.eururo.2006.11.040

Abstract Objective To estimate the annual direct costs of overactive bladder (OAB) in Germany from a societal perspective. Methods Direct costs were calculated based on prevalence figures and medical resource utilisation due to hospitalisation, office-based physician visits, visits to other health care professionals, medication, medical aids and devices, and nursing care. Results A total of 6.48 million adults ≥40 yr of age in Germany are affected by OAB, and 2.18 million of these individuals experience incontinence. The annual incidence of comorbidities attributable to OAB is 310,000 for skin infections, 40,000 for falls, 12,000 for fractures, and 26,000 for depression (based on 2004 census data). Direct OAB-related costs per year are €3.98 billion, with €1.76 billion covered by statutory health insurance, €1.80 billion by nursing care insurance, and €0.41 billion by the patients. Nursing care accounts for €1.80 billion of total costs (45%), devices account for €0.68 billion (17%), physician visits account for €0.65 billion (16%), complications account for €0.75 billion (19%), and medication accounts for €0.08 billion (2%). Conclusion OAB imposes a substantial economic burden on German health and nursing care, insurance, and on patients with OAB. Direct annual costs are comparable to those of other chronic diseases such as dementia or diabetes mellitus.